- Home
- GOF vs PTGX Comparison
GOF vs PTGX Comparison
Compare GOF & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOF | PTGX |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | 141 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 9.3B |
| IPO Year | 2006 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GOF | PTGX |
|---|---|---|
| Price | $8.63 | $143.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $108.23 |
| AVG Volume (30 Days) | ★ 4.0M | 465.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $61.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.51 | $61.95 |
| 52 Week High | $15.11 | $160.81 |
Technical Indicators
Market Signals| Indicator | GOF | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 18.92 | 45.56 |
| Support Level | N/A | $141.95 |
| Resistance Level | $10.74 | $160.81 |
| Average True Range (ATR) | 0.15 | 5.12 |
| MACD | -0.05 | -0.99 |
| Stochastic Oscillator | 9.75 | 26.15 |
Price Performance
Historical ComparisonAbout GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The Fund's investment objective is to maximize total return through a combination of current income and capital appreciation. It has single operating segment. Its products are Mutual Funds, Wealth Management SMAS, Institutional SMAS, ETFS, UITS, UCITS, CIT, Closed-End Funds, Private Funds, Rydex Funds, and Variable Insurance funds.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.